company background image
6550

Polaris Group TPEX:6550 Stock Report

Last Price

NT$109.00

Market Cap

NT$78.4b

7D

-10.3%

1Y

68.0%

Updated

15 May, 2022

Data

Company Financials
6550 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

6550 Stock Overview

Polaris Group provides consulting services to post-acute health care providers in the United States.

Polaris Group Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Polaris Group
Historical stock prices
Current Share PriceNT$109.00
52 Week HighNT$137.50
52 Week LowNT$53.00
Beta0.85
1 Month Change-14.84%
3 Month Change41.19%
1 Year Change67.95%
3 Year Change442.29%
5 Year Change336.00%
Change since IPO-1.21%

Recent News & Updates

Shareholder Returns

6550TW BiotechsTW Market
7D-10.3%-5.1%-3.4%
1Y68.0%9.1%0.7%

Return vs Industry: 6550 exceeded the TW Biotechs industry which returned 9.1% over the past year.

Return vs Market: 6550 exceeded the TW Market which returned 0.7% over the past year.

Price Volatility

Is 6550's price volatile compared to industry and market?
6550 volatility
6550 Average Weekly Movement10.7%
Biotechs Industry Average Movement5.3%
Market Average Movement4.6%
10% most volatile stocks in TW Market8.3%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 6550 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: 6550's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

FoundedEmployeesCEOWebsite
1988n/an/ahttps://www.polaris-group.com

Polaris Group provides consulting services to post-acute health care providers in the United States. The company offers medicare consulting services comprising of operations assessment and training and audits. It also offers mock surveys consisting of nursing facility, as well as clinical compliance consulting and infection control services.

Polaris Group Fundamentals Summary

How do Polaris Group's earnings and revenue compare to its market cap?
6550 fundamental statistics
Market CapNT$78.35b
Earnings (TTM)-NT$740.49m
Revenue (TTM)NT$15.04m

5,210x

P/S Ratio

-105.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6550 income statement (TTM)
RevenueNT$15.04m
Cost of RevenueNT$12.94m
Gross ProfitNT$2.10m
Other ExpensesNT$742.58m
Earnings-NT$740.49m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.03
Gross Margin13.94%
Net Profit Margin-4,923.12%
Debt/Equity Ratio5.5%

How did 6550 perform over the long term?

See historical performance and comparison

Valuation

Is Polaris Group undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


10.86x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6550's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6550's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: 6550 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 6550 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6550's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6550 is overvalued based on its PB Ratio (10.9x) compared to the TW Biotechs industry average (3.8x).


Future Growth

How is Polaris Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


125.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Polaris Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Polaris Group performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


7.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6550 is currently unprofitable.

Growing Profit Margin: 6550 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6550 is unprofitable, but has reduced losses over the past 5 years at a rate of 7.3% per year.

Accelerating Growth: Unable to compare 6550's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6550 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).


Return on Equity

High ROE: 6550 has a negative Return on Equity (-10.26%), as it is currently unprofitable.


Financial Health

How is Polaris Group's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6550's short term assets (NT$6.3B) exceed its short term liabilities (NT$436.8M).

Long Term Liabilities: 6550's short term assets (NT$6.3B) exceed its long term liabilities (NT$171.5M).


Debt to Equity History and Analysis

Debt Level: 6550 has more cash than its total debt.

Reducing Debt: 6550's debt to equity ratio has reduced from 701.7% to 5.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6550 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 6550 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 15.7% each year


Dividend

What is Polaris Group current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6550's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6550's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6550's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6550's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6550 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Polaris Group has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.


Top Shareholders

Company Information

Polaris Group's employee growth, exchange listings and data sources


Key Information

  • Name: Polaris Group
  • Ticker: 6550
  • Exchange: TPEX
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: NT$78.354b
  • Shares outstanding: 718.85m
  • Website: https://www.polaris-group.com

Location

  • Polaris Group
  • 3030 North Rocky Point Drive
  • Suite 240
  • Tampa
  • Florida
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.